ConductScience.org, home

Paper19088047

A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies.

Schimmer AD and 17 others. Clin Cancer Res, 2008. Cited by 154 papers, by iCite.

Cite this record

ConductScience Library. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Papers, record 19088047. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19088047

Download JSON
Disease
acute myeloid leukemia587 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies.
PubMed
Journal
Clin Cancer Res
PubMed
Year
2008
PubMed
Publication types
Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
154
iCite
Relative citation ratio, by iCite
3.18
iCite
Revised in PubMed
2023-02-02
PubMed

Authors18

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Schimmer ADAaron D
2O'Brien SSusan
3Kantarjian HHagop
4Brandwein JJoseph
5Cheson BDBruce D
6Minden MDMark D
7Yee KKaren
8Ravandi FFarhad
9Giles FFrancis
10Schuh AAndre
11Gupta VVikas
12Andreeff MMichael
13Koller CCharles
14Chang HHong
15Kamel-Reid SSuzanne
16Berger MMark
17Viallet JJean
18Borthakur GGautam

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
LeukemiaMajor topic
Proto-Oncogene Proteins c-bcl-2Major topic
PyrrolesMajor topic
Adult
Aged
Aged, 80 and over
Electrocardiography
Female
Humans
Indoles
Male
Middle Aged

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P30CA016672NIH

Source NIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT00438178Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological MalignanciesResults

Source ClinicalTrials.gov

Download CSV of trials

Cited by95

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 154 citations.

PMIDTitleJournalYearIn PapersSource
41596764BCL-2 and BCL-xL in Cancer: Regulation, Function, and Therapeutic Targeting.Int J Mol Sci2026https://conductscience.org/library/papers/41596764PubMed
39456607Insights into Metabolic Reprogramming in Tumor Evolution and Therapy.Cancers (Basel)2024https://conductscience.org/library/papers/39456607PubMed
39060763Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies.Discov Oncol2024https://conductscience.org/library/papers/39060763PubMed
37834104Design, Synthesis, and Potent Anticancer Activity of Novel Indole-Based Bcl-2 Inhibitors.Int J Mol Sci2023https://conductscience.org/library/papers/37834104PubMed
37759469Obatoclax Rescues FUS-ALS Phenotypes in iPSC-Derived Neurons by Inducing Autophagy.Cells2023https://conductscience.org/library/papers/37759469PubMed
37744063Advancement of regulating cellular signaling pathways in NSCLC target therapy via nanodrug.Front Chem2023https://conductscience.org/library/papers/37744063PubMed
37168341The signature of immune-subtype specific driving transcription factors suggest potential drugs for refractory glioblastoma.Am J Cancer Res2023https://conductscience.org/library/papers/37168341PubMed
35571387Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms.Ann Transl Med2022https://conductscience.org/library/papers/35571387PubMed
34753495BH3-mimetics: recent developments in cancer therapy.J Exp Clin Cancer Res2021https://conductscience.org/library/papers/34753495PubMed
33883040Mitochondrial metabolism as a target for acute myeloid leukemia treatment.Cancer Metab2021https://conductscience.org/library/papers/33883040PubMed
33799470Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives.Cancers (Basel)2021https://conductscience.org/library/papers/33799470PubMed
33335095Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy.Signal Transduct Target Ther2020https://conductscience.org/library/papers/33335095PubMed
33256166Design, Synthesis and Evaluation of New Bioactive Oxadiazole Derivatives as Anticancer Agents Targeting Bcl-2.Int J Mol Sci2020https://conductscience.org/library/papers/33256166PubMed
33251145Targeting Bcl-2 Proteins in Acute Myeloid Leukemia.Front Oncol2020https://conductscience.org/library/papers/33251145PubMed
33200242A decision process for drug discovery in retinoblastoma.Invest New Drugs2021https://conductscience.org/library/papers/33200242PubMed
32296028Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia.Signal Transduct Target Ther2020https://conductscience.org/library/papers/32296028PubMed
31941776Identification and Characterization of Novel Compounds with Broad-Spectrum Antiviral Activity against Influenza A and B Viruses.J Virol2020https://conductscience.org/library/papers/31941776PubMed
31938458Mitochondrial Impairment by Cyanine-Based Small Molecules Induces Apoptosis in Cancer Cells.ACS Med Chem Lett2020https://conductscience.org/library/papers/31938458PubMed
31869416Venetoclax for AML: changing the treatment paradigm.Blood Adv2019https://conductscience.org/library/papers/31869416PubMed
31717784Targeting Apoptotic Pathways in Acute Myeloid Leukaemia.Cancers (Basel)2019https://conductscience.org/library/papers/31717784PubMed

See all 95 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
BCL2596PubTator's text mininghttps://conductscience.org/library/genes/596

Source NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
OBATOCLAX MESYLATECHEMBL2107358Results1https://conductscience.org/library/drugs/CHEMBL2107358

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • References
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19088047

GET https://conductscience.org/api/papers/v1/19088047/cited_by?page=2